Last Updated: September 29, 2026

Suppliers and packagers for ANEXSIA 7.5/325


✉ Email this page to a colleague

« Back to Dashboard


ANEXSIA 7.5/325

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Specgx Llc ANEXSIA 7.5/325 acetaminophen; hydrocodone bitartrate TABLET;ORAL 040405 ANDA SpecGx LLC 0406-0124-01 100 TABLET in 1 BOTTLE (0406-0124-01) 2000-09-08
Specgx Llc ANEXSIA 7.5/325 acetaminophen; hydrocodone bitartrate TABLET;ORAL 040405 ANDA SpecGx LLC 0406-0124-05 500 TABLET in 1 BOTTLE (0406-0124-05) 2000-09-08
Specgx Llc ANEXSIA 7.5/325 acetaminophen; hydrocodone bitartrate TABLET;ORAL 040405 ANDA SpecGx LLC 0406-0124-10 1000 TABLET in 1 BOTTLE (0406-0124-10) 2000-09-08
Specgx Llc ANEXSIA 7.5/325 acetaminophen; hydrocodone bitartrate TABLET;ORAL 040405 ANDA SpecGx LLC 0406-0124-23 1 TABLET in 1 BLISTER PACK (0406-0124-23) 2000-09-08
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Subscribe to access the full database, or Start Trial

Suppliers and packagers for ANEXSIA 7.5/325

Last updated: June 25, 2026

Anexsia 7.5/325 Suppliers: Who Makes and Supplies Anexsia (Hydrocodone Bitartrate/Acetaminophen) 7.5 mg/325 mg?

Executive summary: Anexsia 7.5/325 is a fixed-dose combination of hydrocodone bitartrate and acetaminophen. Identifying the correct “suppliers” depends on whether the target is (1) the marketing authorization holder/brand owner, (2) the drug substance (API) manufacturers, (3) the finished-dose product (FDF) contract manufacturers, or (4) the wholesale distribution network. If sufficient, source-specific supplier data is not present for Anexsia 7.5/325 in the available record, no supplier list should be produced.

No source-specific supplier identities, manufacturing sites, or Orange Book distributor/labeler details are provided in the prompt. Therefore, a complete and accurate supplier list cannot be produced.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2026 - 2027
 NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links